Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Volumn 8, Issue 3, 2007, Pages 157-163

  Popat, Rita A ^a   Tanner, Caroline M ^b   van den Eeden, Stephen K ^c   Bernstein, Allan L ^d   Bloch, Daniel A ^a   Leimpeter, Amethyst ^c   McGuire, Valerie ^a   Nelson, Lorene M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PARKINSON S INSTITUTE   (United States)

^c KAISER PERMANENTE   (United States)

^d Kaiser Santa Rosa Medical Center   (United States)

Author keywords

Amyotrophic lateral sclerosis; Anti inflammatory medications; Epidemiology; Non steroidal

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; ALUMINUM MAGNESIUM HYDROXIDE; ANACIN; ASCRIPTIN; ATTAPULGITE; BISMUTH SALICYLATE; CALCIUM CARBONATE; CIMETIDINE; CORTISONE; GAS X; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MYLANTA; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORPHENADRINE CITRATE; PARACETAMOL; PIROXICAM; PREDNISONE; RANITIDINE; SULINDAC; TUMS; TYLENOL 3; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BACKACHE; BLOOD DISEASE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; DRUG EFFECT; FEMALE; FIBROMYALGIA; FOOT PAIN; GENDER; HEADACHE; HEARTBURN; HUMAN; INCIDENCE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MUSCULOSKELETAL PAIN; NEUROPATHIC PAIN; OSTEOARTHRITIS; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; SCIATIC NERVE; SEX DIFFERENCE; SKIN ALLERGY; STOMACH DISEASE; UNITED STATES;

ADULT; AGE FACTORS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALIFORNIA; CASE-CONTROL STUDIES; DATA INTERPRETATION, STATISTICAL; DRUG UTILIZATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK; SEX FACTORS;

EID: 34249983159     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/17482960601179456     Document Type: Article

References (26)

1. McGeer, P. L. and McGeer, E. G. (2001) Inflammation, autotoxicity and Alzheimer's disease. Neurobiol Aging, 22, pp. 799-809.
2. Vila, M., Jackson, L. V. and Guegan, C. (2001) The role of glial cells in Parkinson's disease. Current Opinions in Neurology, 14, pp. 483-489.
3. Hall, E. D., Oostveen, J. A. and Gurney, M. E. (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia, 23, pp. 249-256.
4. Levine, J. B., Kong, J., Nadler, M. and Xu, Z. (1999) Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS). Glia, 28, pp. 215-224.
5. Schiffer, D., Cordera, S., Cavalla, P. and Migheli, A. (1996) Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci, 139, pp. 27-33.
6. Seibert, K., Masferrer, J., Zhang, Y., Gregory, S., Olson, G. and Hauser, S. (1995) Mediation of inflammation by cyclooxygenase-2. Agents Actions, 46, pp. 41-50.
7. O'Banion, M. K. (1999) Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol, 13, pp. 45-82.
8. Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L. and Breitner, J. C. (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology, 59, pp. 880-886.
9. Breitner, J. C., Welsh, K. A., Helms, M. J., Gaskell, P. C., Gau, B. A. and Roses, A. D. (1995) Delayed onset of Alzheimer's disease with non-steroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging, 16, pp. 523-530.
10. t'Veld, B. A. in, Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M. and Stijnen, T. (2001) Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med, 345, pp. 1515-1521.
11. McGeer, P. L., Schulzer, M. and McGeer, E. G. (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology, 47, pp. 425-432.
12. Chen, H., Zhang, S. M., Hernan, M. A., Schwarzschild, M. A., Willett, W. C. and Colditz, G. A. (2003) Non-steroidal anti-inflammatory drugs and the risk of Parkinson's disease. Arch Neurol, 60, pp. 1059-1064.
13. Hernan, M. A., Logroscino, G. and Rodriguez, L. A. Garcia (2006) Non-steroidal anti-inflammatory drugs and the incidence of Parkinson's disease. Neurology, 66, pp. 1097-1099.
14. Krieger, N. (1990)
15. Krieger, N. (1992) Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. Am J Pub Health, 82, pp. 703-710.
16. Tandan, R. (1991) Disorders of the upper and lower motor neuron. Neurology in Clinical Practice, pp. 1708-1717. Butterworth-Heinemann, Boston
17. Brooks, B. R., Miller, R. G., Swash, M., Munsat, T. L. and World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord, 1, pp. 293-299.
18. Hosmer, D. W Jr. and Lemeshow, S. (1989) Applied Logistic Regression, John Wiley & Sons, New York
19. Sansbury, L. B., Millikan, R. C., Schroeder, J. C., Moorman, P. G., North, K. E. and Sandler, R. S. (2005) Use of non-steroidal anti-inflammatory drugs and risk of colon cancer in a population-base, case-control study of African Americans and Whites. Am J Epidemiol, 162, pp. 548-558.
20. Ridker, P. M., Cook, N. R., Lee, I. M., Gordon, D., Gaziano, J. M. and Manson, J. E. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 352, pp. 1293-1304.
21. SAS Institute, Inc. (1999) [computer program] Version 8, SAS Institute Inc., Cary, NC
22. Anderson, G. D. (2005) Sex and racial differences in pharmacological response: Where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health. (Larchmt), 14, pp. 19-29.
23. Meibohm, B., Beierle, I. and Derendorf, H. (2002) How important are gender differences in pharmacokinetics?. Clin Pharmacokinet, 41, pp. 329-342.
24. Sorenson, E. J., Stalker, A. P., Kurland, L. T. and Windebank, A. J. (2002) Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology, 59, pp. 280-282.
25. Signorello, L. B., McLaughlin, J. K., Lipworth, L., Friis, S., Sorensen, H. T. and Blot, W. J. (2002) Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther, 9, pp. 199-205.
26. Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Zhang, H., Andreasson, K. I. and Rothstein, J. D. (2006) Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol, 60, pp. 22-31.